For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The price of Repligen Corp (NASDAQ: RGEN) closed at $167.31 in the last session, down -0.65% from day before closing price of $168.4. In other words, the price has decreased by -$0.65 from its previous closing price. On the day, 1.0 million shares were traded. RGEN stock price reached its highest trading level at $172.51 during the session, while it also had its lowest trading level at $161.08.
Ratios:
We take a closer look at RGEN’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.58 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 88.45. For the most recent quarter (mrq), Quick Ratio is recorded 7.14 and its Current Ratio is at 8.36. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.32.
Upgrades & Downgrades
In the most recent recommendation for this company, HSBC Securities on October 01, 2025, initiated with a Buy rating and assigned the stock a target price of $150.
On September 22, 2025, Evercore ISI Upgraded its rating to Outperform which previously was In-line but kept the price unchanged to $155.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 17 ’25 when DAWES KAREN A sold 275 shares for $161.00 per share. The transaction valued at 44,275 led to the insider holds 91,821 shares of the business.
DAWES KAREN A bought 275 shares of RGEN for $44,275 on Dec 17 ’25. On Nov 25 ’25, another insider, Loeillot Olivier, who serves as the Chief Executive Officer of the company, sold 7,041 shares for $170.00 each. As a result, the insider received 1,196,970 and left with 35,898 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGEN now has a Market Capitalization of 9418004480 and an Enterprise Value of 9358125056. As of this moment, Repligen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 6510.12, and their Forward P/E ratio for the next fiscal year is 80.55. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.22. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.30 while its Price-to-Book (P/B) ratio in mrq is 4.52. Its current Enterprise Value per Revenue stands at 13.22 whereas that against EBITDA is 68.197.
Stock Price History:
The Beta on a monthly basis for RGEN is 1.14, which has changed by 0.07063389 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, RGEN has reached a high of $182.52, while it has fallen to a 52-week low of $102.96. The 50-Day Moving Average of the stock is 4.21%, while the 200-Day Moving Average is calculated to be 22.61%.
Shares Statistics:
According to the various share statistics, RGEN traded on average about 798.98K shares per day over the past 3-months and 552210 shares per day over the past 10 days. A total of 56.28M shares are outstanding, with a floating share count of 53.22M. Insiders hold about 5.45% of the company’s shares, while institutions hold 107.95% stake in the company. Shares short for RGEN as of 1767139200 were 3933025 with a Short Ratio of 4.92, compared to 1764288000 on 4309467. Therefore, it implies a Short% of Shares Outstanding of 3933025 and a Short% of Float of 9.42.
Earnings Estimates
The stock of Repligen Corp (RGEN) is currently drawing attention from 18.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $0.44, with high estimates of $0.51 and low estimates of $0.31.
Analysts are recommending an EPS of between $1.7 and $1.64 for the fiscal current year, implying an average EPS of $1.67. EPS for the following year is $2.07, with 19.0 analysts recommending between $2.47 and $1.76.
Revenue Estimates
According to 18 analysts,. The current quarter’s revenue is expected to be $193.02M. It ranges from a high estimate of $196M to a low estimate of $189M. As of. The current estimate, Repligen Corp’s year-ago sales were $167.55MFor the next quarter, 18 analysts are estimating revenue of $191.98M. There is a high estimate of $197M for the next quarter, whereas the lowest estimate is $186.9M.
A total of 20 analysts have provided revenue estimates for RGEN’s current fiscal year. The highest revenue estimate was $737M, while the lowest revenue estimate was $729.3M, resulting in an average revenue estimate of $733.13M. In the same quarter a year ago, actual revenue was $634.44MBased on 19 analysts’ estimates, the company’s revenue will be $823.87M in the next fiscal year. The high estimate is $834.56M and the low estimate is $794.14M.
